Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 78

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 78
---
.

We
currently expect that our cash and cash equivalents will only be sufficient to fund our operations, development plans, and capital expenditures
through the third quarter of 2026. As such, there is substantial doubt about the Company’s ability to continue as a going concern.

We
did not have any material non-cancellable contractual obligations as of September 30, 2025.

18

Cash
Flows

The
following table provides information regarding our cash flows for the periods presented:

    Nine Months Ended 

    September 30, 

    2025  
    2024 
  
    Net cash provided by (used in): 

    Operating activities 
    $(2,486,841) 
    $(4,464,620)
  
    Financing activities 
     8,550,008  
     5,298,027 
  
    Net change in cash 
    $6,063,167  
    $833,407 

Net
Cash from Operating Activities

The
cash used in operating activities resulted primarily from our net losses, stock-based compensation expenses and changes in components
of accounts payable, accrued liabilities, and prepaid expenses.

For
the nine months ended September 30, 2025, operating activities used $2.5 million of cash, primarily due to a net loss of $8.4 million,
stock compensation costs of $6.1 million and a $0.3 million change in accounts payable, accrued liabilities and prepaid expenses. Accounts
payable, accrued and prepaid expenses was primarily composed of research and development payables, consultant costs, insurance costs,
legal and accounting expenses.

For
the nine months ended September 30, 2024, operating activities used $4.5 million of cash, primarily due to a net loss of $13.6 million
offset by $0.03 million change in accounts payable, accrued and prepaid expenses. In the nine months ended September 30, 2024, we recognized
$4.3 million in the amortization of debt issuance costs and $4.8 million in stock-based compensation.

Accounts
payable, accrued and prepaid expenses was primarily composed of research and development payables, consultant costs, insurance costs,
legal and accounting expenses.

Net
Cash from Financing Activities

For
the nine months ended September 30, 2025, financing activities provided $8.6 million of cash, resulting primarily from net proceeds from
the sale of common stock.

For
the nine months